Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

2009 Version of the Chompret Criteria for Li Fraumeni Syndrome

2009 Version of the Chompret Criteria for Li Fraumeni Syndrome VOLUME 27  NUMBER 26  SEPTEMBER 10 2009 CORRESPONDENCE JOURNAL OF CLINICAL ONCOLOGY 2009 Version of the Chompret Criteria Table 1. 2009 Chompret Criteria for Germline TP53 Mutation Screening Criterion for Li Fraumeni Syndrome I. Proband with tumor belonging to LFS tumor spectrum (eg, soft tissue sarcoma, osteosarcoma, brain tumor, TO THE EDITOR: We read with great interest the article by premenopausal breast cancer, adrenocortical carcinoma, leukemia, lung bronchoalveolar cancer) before age 46 years Gonzalez et al published in Journal of Clinical Oncology. This study AND at least one first- or second-degree relative with LFS confirms the clinical utility of the Chompret criteria, which the French tumor (except breast cancer if proband has breast cancer) before age 56 years or with multiple tumors; OR Li Fraumeni syndrome (LFS) working group elaborated in 2001 to 2 II. Proband with multiple tumors (except multiple breast tumors), facilitate diagnosis of LFS. Gonzalez et al performed TP53 analysis in two of which belong to LFS tumor spectrum and first of 341 clinically informative families, including 195 families fulfilling the which occurred before age 46 years; OR III. Patient with adrenocortical carcinoma or choroid plexus Chompret criteria; obtained a mutation detection rate of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Oncology Wolters Kluwer Health

Loading next page...
 
/lp/wolters-kluwer-health/2009-version-of-the-chompret-criteria-for-li-fraumeni-syndrome-lzCOR5dqt8

References (3)

Publisher
Wolters Kluwer Health
Copyright
(C) 2009 American Society of Clinical Oncology
ISSN
0732-183X
eISSN
1527-7755
DOI
10.1200/JCO.2009.22.7967
Publisher site
See Article on Publisher Site

Abstract

VOLUME 27  NUMBER 26  SEPTEMBER 10 2009 CORRESPONDENCE JOURNAL OF CLINICAL ONCOLOGY 2009 Version of the Chompret Criteria Table 1. 2009 Chompret Criteria for Germline TP53 Mutation Screening Criterion for Li Fraumeni Syndrome I. Proband with tumor belonging to LFS tumor spectrum (eg, soft tissue sarcoma, osteosarcoma, brain tumor, TO THE EDITOR: We read with great interest the article by premenopausal breast cancer, adrenocortical carcinoma, leukemia, lung bronchoalveolar cancer) before age 46 years Gonzalez et al published in Journal of Clinical Oncology. This study AND at least one first- or second-degree relative with LFS confirms the clinical utility of the Chompret criteria, which the French tumor (except breast cancer if proband has breast cancer) before age 56 years or with multiple tumors; OR Li Fraumeni syndrome (LFS) working group elaborated in 2001 to 2 II. Proband with multiple tumors (except multiple breast tumors), facilitate diagnosis of LFS. Gonzalez et al performed TP53 analysis in two of which belong to LFS tumor spectrum and first of 341 clinically informative families, including 195 families fulfilling the which occurred before age 46 years; OR III. Patient with adrenocortical carcinoma or choroid plexus Chompret criteria; obtained a mutation detection rate of

Journal

Journal of Clinical OncologyWolters Kluwer Health

Published: Sep 10, 2009

There are no references for this article.